Preview

PDF 146593 - bioequ...pdf | Download (4MB) | Preview

Abstract

Background: Regorafenib is an oral multi-kinase inhibitor approved for the treatment of solid tumours, but the pharmacokinetic profile of regorafenib in the Chinese population is unclear.Objective: The aim of this study was to examine the pharmacokinetics, bioequivalence, and safety of two formulations of regorafenib 40 mg in healthy Chinese volunteers under fed and fasting conditions.Methods: A single-centre, randomised, open-label, two-period, two-way crossover phase 1 trial was conducted by randomising a single oral dose of test (T) or reference (R, Stivarga®) regorafenib (40 mg) to healthy Chinese volunteers under both fasting and fed conditions (high-fat and high-calorie diet). Pharmacokinetic parameters were calculated using non-compartmental methods. Adverse events were recorded to assess drug safety.Results: Sixty-six participants were enrolled for both fasting and fed treatments. The 90% CIs geometric least-square means of ratioT/R for regorafenib were completely contained within the equivalence margin of 80-125% under both fasting and fed conditions. Both formulations displayed similar and generally good safety profiles.Conclusion: Single oral dose of the T (40 mg) and R (40 mg) regorafenib was bioequivalent under fasting and fed conditions and had similar favourable safety profiles among healthy Chinese volunteers.

Item Type:	Article
Authors/Creators:	Zhang, Q and Wang, Z and Wu, J and Zhou, Z and Zhou, R and Hu, W
Keywords:	regorafenib, phase 1, pharmacokinetic, bioequivalence, Chinese healthy volunteers
Journal or Publication Title:	Drug Design, Development and Therapy
Publisher:	Dove Press Limited
ISSN:	1177-8881
DOI / ID Number:	10.2147/DDDT.S323169
Copyright Information:	Copyright 2021 Zhang et al. Licensed under Creative Commons Attribution-NonCommercial 3.0 Unported (CC BY-NC 3.0) https://creativecommons.org/licenses/by-nc/3.0/
Item Statistics:	View statistics for this item

Actions (login required)

Item Control Page